跳转至内容
Merck
CN

HCYTA-60K

MILLIPLEX® Human Cytokine/Chemokine/Growth Factor Panel A

Configurable Human Cytokine/Chemokine/Growth Factor 48-Plex Panel A

别名:

Human cytokine multiplex kit, Luminex® human cytokine immunoassay, Millipore human cytokine panel

登录 查看组织和合同定价。

关于此项目

NACRES:
NA.84
UNSPSC Code:
12161503
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

产品名称

MILLIPLEX® Human Cytokine/Chemokine/Growth Factor Panel A, Configurable Human Cytokine/Chemokine/Growth Factor 48-Plex Panel A

Quality Level

species reactivity

human

packaging

pkg of 1 ea

manufacturer/tradename

Milliplex®

technique(s)

multiplexing: suitable

input

cell culture supernatant
serum

detection method

fluorometric (Luminex® xMAP® technology)

shipped in

wet ice

storage temp.

2-8°C

Legal Information

Luminex is a registered trademark of Luminex Corp
MILLIPLEX is a registered trademark of Merck KGaA, Darmstadt, Germany
xMAP is a registered trademark of Luminex Corp

Application

MILLIPLEX® Qualified assays undergo rigorous assay development, verification, and Quality Control testing to achieve optimal performance. Simultaneously analyze up to 48 analytes in human serum, plasma, and cell culture supernatants.Analytes included: sCD40L, EGF, Eotaxin/CCL11, FGF-2/FGF-basic, FLT-3L, Fractalkine/CX3CL1, G-CSF, GM-CSF, GROα, IFNα2, IFNγ, IL-1α, IL-1β, IL-1RA, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12 (p40), IL-12(p70), IL-13, IL-15, IL-17A/CTLA8, IL-17E/IL-25, IL-17F, IL-18, IL-22, IL-27, IP-10/CXCL10, MCP-1/CCL2, MCP-3/CCL7, M-CSF, MDC, MIG/CXCL9, MIP-1α/CCL3, MIP-1β/CCL4, PDGF-AA, PDGF-AB/BB, RANTES/CCL5, TGFα, TNFα, TNFβ/LTA, VEGF-ANote: RANTES cannot be plexed with other cytokines in this panel due to a required 1:100 dilution of plasma/serum samples.Assay Characteristics: Refer to kit protocol for assay cross-reactivity, sensitivity, precision, and accuracy.

Disclaimer

For research use only. Not for use in diagnostic procedures.Label License/Sticker for Assay Product:By opening the packaging containing this Assay Product (which contains fluorescently labeled microsphere beads authorized by Luminex Corporation) or using this Assay Product in any manner, you are consenting and agreeing to be bound by the End User Terms and Conditions and the End User License Agreement available at http://support.diasorin.com/end-user-terms-and-conditions/. If you do not agree to all of the terms and conditions, you must promptly return this Assay Product for a full refund prior to using it in any manner.

Features and Benefits

48-Plex Power, Simplified: One kit unlocks 48 biomarkers—replaces multiple ELISAs and slashes costs.More Than 20-Year Multiplexing Legacy: The original multiplex innovator—trusted by top pharma companies for critical assays.Cancer, Autoimmunity, & Beyond: Power research in immunotherapy, sepsis, Alzheimer′s, and Long COVID biomarker discovery.Intuitive Workflow: User-friendly protocols that require minimal training, allowing researchers to achieve publication-ready results without extensive background in multiplex assays.Configurable Assay Design: Configure your panel by selecting specific analytes based on your research needs, allowing for a tailored approach that maximizes relevance and impact.Robust Sample Compatibility: Verified for serum, plasma, PBMC supernatants, and cell/tissue lysates. Tested across normal and disease-state samples for broad applicability.Peer-Reviewed Credibility: Frequently cited in immunology and clinical research publications. Trusted by academic institutions, CROs, and pharma companies.Performance Highlights from Comparative Studies: MILLIPLEX® assays showed highest reproducibility among Luminex®-based kits in a head-to-head study and in disease profiling (e.g., ovarian cancer, sepsis), and MILLIPLEX® assays detected more significantly elevated analytes than competitors.Global Support & Documentation: Backed by extensive technical documentation, protocols, and customer support.

signalword

Danger

Hazard Classifications

Acute Tox. 4 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral - Aquatic Chronic 2 - Eye Dam. 1 - Skin Sens. 1 - STOT RE 2

target_organs

Respiratory Tract

存储类别

10 - Combustible liquids

法规信息

新产品
此项目有

分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Carl A Pierce et al.
medRxiv : the preprint server for health sciences (2021-02-18)
COVID-19 is more benign in children compared to adults for unknown reasons. This contrasts with viruses such as influenza where disease manifestations are often more severe in children1. We hypothesized that a more robust early innate immune response to SARS-CoV-2
Carl A Pierce et al.
JCI insight, 6(9) (2021-04-07)
BACKGROUNDCoronavirus disease 2019 (COVID-19) is more benign in children compared with adults for unknown reasons. This contrasts with other respiratory viruses where disease manifestations are often more severe in children. We hypothesize that a more robust early innate immune response
Yiwei Zhao et al.
Fertility and sterility, 115(4), 1044-1053 (2020-12-05)
To compare the changing peripheral levels of inflammation-related cytokine profile during a 9-day period after blastocyst transfer between women who did and did not conceive. Prospective, observational, and longitudinal study. University-affiliated hospital. Forty-seven women with infertility who were undergoing single
Kelsey E Huntington et al.
eLife, 10 (2021-01-15)
Although the range of immune responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is variable, cytokine storm is observed in a subset of symptomatic individuals. To further understand the disease pathogenesis and, consequently, to develop an additional tool for
Teslin S Sandstrom et al.
Journal of virology, 95(9) (2021-02-12)
The use of unique cell surface markers to target and eradicate HIV-infected cells has been a longstanding objective of HIV-1 cure research. This approach, however, overlooks the possibility that intracellular changes present within HIV-infected cells may serve as valuable therapeutic

相关内容

通过适合的免疫检测产品,探索神经免疫和神经炎症细胞因子及神经退行性疾病生物标志物。

Cytokine multiplex assays allow researchers to easily investigate the immune system. The MILLIPLEX® Human Cytokine/Chemokine/Growth Factor Multiplex Panels A and B are multiplex assays for cytokine detection that each offer a unique combination of 48 analytes that can be simultaneously analyzed in a small sample volume.

Immunology multiplex assays, like MILLIPLEX® assays, allow researchers to investigate more immune biomarkers simultaneously, saving time and resources.

Discover the benefits of MILLIPLEX® multiplex assays, based on Luminex® xMAP® multiplex assay technology, that provide consistent, high-quality results and see how these multiplex biomarker Luminex® assays are being used to advance research.

查看所有结果

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持